Chapter

Alzheimer Disease

Part of the series Advances in Alzheimer Disease Therapy pp 425-429

Validity and Reliability of the Alzheimer’s Disease Cooperative Study-Clinical Global Impression of Change (ADCS-CGIC)

  • Lon S. SchneiderAffiliated withDepartment of Psychiatry, School of Geronotology, University of Southern CaliforniaDepartment of Neurology, School of Geronotology, University of Southern California
  • , Jason T. OlinAffiliated withDepartment of Psychiatry, School of Geronotology, University of Southern California
  • , Rachelle S. DoodyAffiliated withDepartment of Neurology, Baylor College of Medicine
  • , Christopher M. ClarkAffiliated withDepartment of Neurology, University of Pennsylvania School of Medicine
  • , John C. MorrisAffiliated withDepartment of Neurology, Washington University School of Medicine
  • , Barry ReisbergAffiliated withDepartment of Psychiatry, New York University Medical Center
  • , Steven H. FerrisAffiliated withDepartment of Psychiatry, New York University Medical Center
  • , Frederick A. SchmittAffiliated withDepartment of Neurology, University of Kentucky
  • , Michael GrundmanAffiliated withDepartment of Psychiatry, Southern Illinois University School of MedicineUniversity of California
    • , Ronald G. ThomasAffiliated withDepartment of Psychiatry, Southern Illinois University School of MedicineUniversity of California

* Final gross prices may vary according to local VAT.

Get Access

Abstract

Clinical global impressions of change (CGICs) are important measures of efficacy in clinical trials. CGIC scales have been used extensively as primary outcome criteria in psychopharmacological trials and in early clinical trials for antidementia drugs (e.g., Schneider and Olin, 1994). CGICs have been reported to be the most sensitive index of change in 14 of 17 dementia trials, when compared to other measures (Lehmann, 1984).